Physician profile
John E Muscalus
NPI 1710919774
$5,060.48
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,367 · 2020: $868 · 2021: $1,376 · 2022: $1,158 · 2023: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,002.39 | 2019-2023 | Farxiga |
| Abbvie INC. | $459.65 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $441.89 | 2019-2023 | Trintellix |
| Novo Nordisk INC | $392.04 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $290.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $277.83 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $257.44 | 2020-2023 | Otezla, Repatha |
| Allergan, INC. | $239.99 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $230.90 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.72 | 2019-2023 | Tradjenta, Jardiance |
| Pfizer INC. | $185.51 | 2019-2021 | |
| Amarin Pharma, INC. | $180.36 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $144.01 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $143.05 | 2019-2022 | |
| Lilly USA, LLC | $135.53 | 2019-2023 | Mounjaro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $111.16 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $53.49 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $42.14 | 2021-2022 | |
| Esperion Therapeutics, INC. | $31.10 | 2021 | |
| Mylan Specialty L.P. | $28.43 | 2021-2022 | |
| Astellas Pharma US INC | $28.06 | 2019 | |
| Abbott Laboratories | $27.28 | 2022 | |
| Bausch Health US, LLC | $22.08 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.73 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.73 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.57 | 2020 | |
| Ibsa Pharma INC. | $16.71 | 2023 | Tirosint, Licart |
| Exact Sciences Corporation | $16.12 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $15.99 | 2022 | |
| Mannkind Corporation | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Muscalus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.